MarginsXMarginsX
Home › Markets › Health Care › KLRS

Kalaris Therapeutics Inc. (KLRS)

KLRS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.46
-7.30% on the day
Market cap
$34.8M
Nano cap
Revenue · 2019
$165K
No prior year to compare
Net income · 2019
-$23.8M
-14447.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/1754068/000156459021005652/0001564590-21-005652-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.

Profile

FieldValue
TickerKLRS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001754068
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2019

LineValue
Revenue$165K
Net income-$23.8M
Operating income-$26.7M
Net margin-14447.9%
Operating margin-16182.4%
Revenue growthNo prior-year revenue to compare
Cash$61.1M
Total assets$139.4M
P/E (computed)Net income was not positive
P/S (computed)210.6×

Warning signs

Cash runway
14.1 months
$47.4M cash at September 30, 2026
Share count, 1 year
+27.3%
2025-11-05 to 2026-11-03 · +380.0% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$6.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$47.4M cash; operating cash flow -$10.1M a quarter.Report 2026-09-30
Shares outstanding23,804,981 (2026-11-03); 18,702,418 a year earlier; 114,063,336 three years earlier. 3y figure adjusted for split (1-for-23 overall).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-23 on 2025-01-16Source 2025-01-16
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $6.2M, sold $13K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$11.0M-$10.6M$47.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$11.5M-$11.0M$43.2MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$10.9M-$11.6M$34.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$10.0M-$7.1M$98.1M$0Needs four quarters10-K 2026-03-17
Q3 2025
2025-09-30
Not filed-$11.9M-$11.3M$42.4M$0Needs four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$11.3M-$12.5M$88.4M$0Needs four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$10.2M-$7.4M$101.0M$0Needs four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$22.0M-$7.9M$1.6M$19.5MNeeds four quarters10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-13
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 701 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-34.9%
1 month-29.4%
3 months-59.4%
Year to date-81.3%
1 year-70.5%
From 52-week high-85.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ELUTElutia Inc.$0.8229+0.35%$36.5M
EXOZeXoZymes Inc.$3.99+4.18%$37.1M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
TILInstil Bio Inc.$5.75-5.43%$39.0M
LONALeonaBio Inc.$3.23-6.92%$30.4M
IMAImageneBio Inc.$3.20-7.78%$39.9M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
CVMCel-Sci Corporation$1.66+29.69%$29.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier